Antibody specifically recognizing an epitope for switching to TH1 cell
US-9255151-B2 · Feb 9, 2016 · US
GITR antibodies, methods, and uses
US10730950B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10730950-B2 |
| Application number | US-201715453451-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 8, 2017 |
| Priority date | Mar 8, 2016 |
| Publication date | Aug 4, 2020 |
| Grant date | Aug 4, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are antibodies that specifically bind to GITR. Also described are related polynucleotides capable of encoding the provided GITR-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to enhance an immune response in a subject against cancer.
First claim
Opening claim text (preview).
We claim: 1. An isolated antibody, or an antigen-binding fragment thereof, that specifically binds to human GITR comprising a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 27, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 5, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 26, a light chain CDR1 having the amino acid sequence of SEQ ID NO: 28, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 32, and a light chain CDR3 having the amino acid sequence of SEQ ID NO: 35. 2. The antibody or an antigen-binding fragment of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises SEQ ID NO: 64. 3. The antibody or an antigen-binding fragment of claim 2 , wherein the antibody or antigen binding fragment thereof comprises a light chain region comprising SEQ ID NO: 55. 4. The antibody or antigen-binding fragment of claim 1 wherein the antibody or antigen-binding fragment thereof specifically binds human GITR with a binding affinity of at least 30 nM as measured by surface plasmon resonance. 5. The antibody or antigen-binding fragment of claim 1 wherein the antibody or antigen-binding fragment induces ADCC in vitro with an EC 50 of less than about 67 ng/mL. 6. The antibody or antigen-binding fragment of claim 1 wherein the antibody or antigen-binding fragment is a human antibody or antigen-binding fragment. 7. The antigen-binding fragment of claim 1 wherein the antigen binding fragment is a Fab fragment, a Fab2 fragment, or a single chain antibody. 8. The antibody or antigen-binding fragment of claim 1 wherein the antibody or antigen-binding fragment is recombinant. 9. The antibody or antigen-binding fragment of claim 1 wherein the antibody or antigen-binding fragment thereof are of IgG1, IgG2, IgG3, or IgG4 isotype. 10. The antibody or antigen-binding fragment of claim 1 is IgG1 isotype. 11. A pharmaceutical composition comprising the antibody, or antigen binding fragment thereof, of claim 1 and a pharmaceutically acceptable carrier. 12. A kit comprising the antibody, or antigen binding fragment thereof, of claim 1 .
Assignees
Inventors
Classifications
Cancer antigens · CPC title
Framework region [FR] · CPC title
Clostridium, e.g. Clostridium tetani · CPC title
against receptors for cytokines, lymphokines, interferons · CPC title
wherein the target is cancer · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10730950B2 cover?
- Provided herein are antibodies that specifically bind to GITR. Also described are related polynucleotides capable of encoding the provided GITR-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the prov…
- Who is the assignee on this patent?
- Janssen Biotech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2818. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).